PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Concluding discussion.

8 November 2019 (15:10 - 15:20)

Organised by:

Video

Sign in for access options

5 More presentations in this session

Presentation thumbnail

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure - Pro.

Associate Professor D. Sim (Singapore, SG)

Presentation thumbnail

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure- Contra.

Professor J. Cleland (Glasgow, GB)

Presentation thumbnail

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure concluding discussion.

Presentation thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.

Professor M. Marwan (Erlangen, DE)

Presentation thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Contra

Associate Professor K. Sin (Singapore, SG)

Access the full session

Session thumbnail

Controversies in 2019

The Event

ESC Asia with APSC & AFC

8 November 2019 15:10 CET

You may be interested in

Congress Presentation

Coronary artery bypass grafting versus percutaneous coronary intervention for left main disease in chronic kidney disease patients: A meta-analysis

28 August 2020

Congress Presentation

Discussions.

28 August 2022

Webinar

The year in cardiology 2018

12 December 2018

Congress Presentation

Timing of invasive strategy in non-ST segment elevation acute coronary syndrome (NSTE-ACS) and chronic kidney disease: could it influence the occurrence of arrhythmic and pump failure events?

21 May 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources